Search for Topics:
Title/Keyword
Journal
Submission Status
Category
 
 
Topics
Rheumatic Disorder: From Basic Science to Clinical Practice—2nd Edition
Submit your Manuscript Propose a Topic

Topic Menu

► Topic Menu

Topic Editors

Dr. Andreina Manfredi
Rheumatology Unit, Azienda Ospedaliera Universitaria Policlinico of Modena, 41121 Modena, Italy
Dr. Caterina Vacchi
Rheumatology Unit, Azienda Policlinico di Modena, University of Modena and Reggio Emilia, 41121 Modena, Italy
Rheumatology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, 41125 Modena, Italy
share announcement

Rheumatic Disorder: From Basic Science to Clinical Practice—2nd Edition

Abstract submission deadline
closed (20 June 2026)
Manuscript submission deadline
20 September 2026
Viewed by
1542

Topic Information

Dear Colleagues,

Autoimmune rheumatic diseases (RDs) are chronic inflammatory diseases with a major health impact worldwide, but their management and classification are sometimes difficult due to their unknown aetiology and the heterogeneity of their clinical presentation. RDs have the largest and most consistent impact across all age groups, and they affect a significant proportion of the population. Their economic and social burden results from a decreased quality of life, a loss of productivity, and the increased costs of health care. Moreover, although RDs affect people of all ages, the demographic structure of the population indicates an increasing tendency towards an older population, along with an increasing prevalence of these diseases. Therefore, improving our knowledge of RDs, from basic science to clinical practice, has become critical. The heterogeneity of RDs and the lack of any clear clinical correlation with pathology makes for an inexact estimation of their incidence and prevalence. Moreover, more investigation is needed concerning the causes and mechanisms affecting the development and progression of these disorders, and more studies are needed to discover innovative treatments. As a result, the challenges of studying RDs lie in achieving accurate epidemiological data and making efforts to attain significant progress in determining the etiological mechanisms, clinical behaviour, and the genetic/epigenetic basis of the diseases, as well as the early diagnosis, treatment, and management of patients.

Dr. Andreina Manfredi
Dr. Caterina Vacchi
Dr. Giulia Cassone
Topic Editors

Keywords

  • rheumatic diseases
  • aetiology
  • epidemiology
  • therapy
  • diagnosis
  • classification
  • risk factors

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biomedicines
biomedicines 		4.5 7.8 2013 18.2 Days CHF 2600 Submit
Clinics and Practice
clinpract 		2.8 3.5 2011 24 Days CHF 1800 Submit
Diagnostics
diagnostics 		3.8 6.9 2011 20.4 Days CHF 2600 Submit
Journal of Clinical Medicine
jcm 		3.3 5.2 2012 16.6 Days CHF 2600 Submit
Rheumato
rheumato 		- - 2021 30 Days CHF 1000 Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

  1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
  2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
  3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
  4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
  5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results
Result details
Journals
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
10 pages, 420 KB  
Systematic Review
Mepolizumab Versus Benralizumab for the Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis
by Andrew Lurie, Danielle Madison, Jason Baluja, Sandra Madathilethu and Anas Bizanti
Rheumato 2026, 6(3), 15; https://doi.org/10.3390/rheumato6030015 - 2 Jul 2026
Viewed by 111
Abstract
Background: IL-5 inhibitors are effective at inducing remission in EGPA but the comparative benefit of specific drugs has been poorly studied. Methods: A comprehensive search of PubMed and EMBASE was conducted on 10 October 2025 to identify all studies that directly compare mepolizumab [...] Read more.
Background: IL-5 inhibitors are effective at inducing remission in EGPA but the comparative benefit of specific drugs has been poorly studied. Methods: A comprehensive search of PubMed and EMBASE was conducted on 10 October 2025 to identify all studies that directly compare mepolizumab with benralizumab in the treatment of EGPA. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 and ROBINS-I V2 tools. Data extraction and statistical analysis were performed using RevMan software to calculate Odds’ Ratios and assess heterogeneity with the I2 statistic. Results: Three studies including a total of 365 participants were analyzed. All patients failed prior treatment, and most patients had a BVAS > 2 and glucocorticoid doses of 10 mg or higher. There was no difference in induction of clinical remission with mepolizumab as compared to benralizumab (OR 0.66 [95% CI 0.43–1.01], I2 = 0%). There was decreased odds of glucocorticoid discontinuation with mepolizumab (OR 0.61 [95% CI: 0.38–0.99], I2 = 0%). There was no difference in achieving glucocorticoid dose less than 5 mg (OR 0.73 [95% CI: 0.18–2.91], I2 = 26%), adverse events (OR 1.26 [95% CI: 0.51–3.12], I2 = 8%), or adverse events requiring discontinuation of therapy (OR 0.62 [95% CI: 0.21–1.85], I2 = 62%). Conclusions: Both benralizumab and mepolizumab effectively induced remission in EGPA. There was a reduced odds of glucocorticoid discontinuation with mepolizumab thus there is a need for prospective head-to-head trials powered to detect a relative glucocorticoid-sparing effect to further assess this finding. Full article
(This article belongs to the Topic Rheumatic Disorder: From Basic Science to Clinical Practice—2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop